J. Milnes

发表

Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel.

J. Hancox, H. Witchel, J. Ridley, 2006, Journal of molecular and cellular cardiology.

hERG K+ channel blockade by the antipsychotic drug thioridazine: An obligatory role for the S6 helix residue F656.

J. Hancox, H. Witchel, D. Leishman, 2006, Biochemical and biophysical research communications.

Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.

Jules C Hancox, Derek J Leishman, Harry J Witchel, 2010, Journal of pharmacological and toxicological methods.

Inhibition of the HERG K+ channel by the antifungal drug ketoconazole depends on channel gating and involves the S6 residue F656

J. Hancox, H. Witchel, A. James, 2006, FEBS letters.

The Low-Potency, Voltage-Dependent HERG Blocker Propafenone—Molecular Determinants and Drug Trapping

Jules C Hancox, Richard B Sessions, Harry J Witchel, 2004, Molecular Pharmacology.

Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652

J. Hancox, O. Crociani, A. Arcangeli, 2003, British journal of pharmacology.

Lidoflazine is a high affinity blocker of the HERG K(+)channel.

J. Hancox, H. Witchel, J. Ridley, 2004, Journal of molecular and cellular cardiology.

High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656.

Jules C Hancox, Harry J Witchel, James T Milnes, 2004, Biochemical and biophysical research communications.

Effect of selective IK,ACh inhibition by XAF‐1407 in an equine model of tachypacing‐induced persistent atrial fibrillation

U. Schotten, U. Sørensen, P. Platonov, 2020, British journal of pharmacology.

The Acetylcholine-Activated Potassium Current Inhibitor XAF-1407 Terminates Persistent Atrial Fibrillation in Goats

U. Schotten, S. Verheule, A. van Hunnik, 2021, Frontiers in Pharmacology.

Pharmacological inhibition of acetylcholine-regulated potassium current (IK,ACh) prevents atrial arrhythmogenic changes in a rat model of repetitive obstructive respiratory events

T. Jespersen, M. Hohl, B. Linz, 2021, Heart rhythm O2.

Activation of Glibenclamide-Sensitive ATP-Sensitive K+ Channels During &bgr;-Adrenergically Induced Metabolic Stress Produces a Substrate for Atrial Tachyarrhythmia

J. Hancox, Shang-Jin Kim, A. James, 2012, Circulation. Arrhythmia and electrophysiology.

Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes.

Jules C Hancox, Harry J Witchel, James T Milnes, 2002, Journal of pharmacological and toxicological methods.

Preferential closed channel blockade of HERG potassium currents by chemically synthesised BeKm‐1 scorpion toxin

J. Hancox, O. Crociani, A. Arcangeli, 2003, FEBS letters.

Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology

Robert Passier, Christine L Mummery, James T Milnes, 2015, EMBO molecular medicine.

Novel K+ Channel Targets in Atrial Fibrillation Drug Development—Where Are We?

J. Milnes, S. El-Haou, J. Ford, 2015, Journal of cardiovascular pharmacology.

Inhibition of voltage-gated Na+ currents by eleclazine in rat atrial and ventricular myocytes

J. Hancox, Hongwei Cheng, B. Clennell, 2020, Heart rhythm O2.

New Drugs Targeting the Cardiac Ultra-Rapid Delayed-Rectifier Current (IKur): Rationale, Pharmacology and Evidence for Potential Therapeutic Value

J. Milnes, J. Ford, 2008, Journal of cardiovascular pharmacology.

New pharmacological approaches to atrial fibrillation.

David Madge, J. Milnes, J. Ford, 2012, Drug discovery today.

Effects of IKur blocker MK-0448 on human right atrial action potentials from patients in sinus rhythm and in permanent atrial fibrillation

Ursula Ravens, Erich Wettwer, Simone Loose, 2014, Front. Pharmacol..

Characterisation of AnBEST1, a functional anion channel in the plasma membrane of the filamentous fungus, Aspergillus nidulans.

M. Caddick, J. Milnes, S. Roberts, 2011, Fungal genetics and biology : FG & B.

The N588K-HERG K+ channel mutation in the ‘short QT syndrome’: Mechanism of gain-in-function determined at 37 °C

Jules C. Hancox, Harry J. Witchel, Mark J. McPate, 2005 .

The positive frequency-dependent electrophysiological effects of the IKur inhibitor XEN-D0103 are desirable for the treatment of atrial fibrillation

Ursula Ravens, Erich Wettwer, Simone Loose, 2016, Heart rhythm.

Human Electrophysiological and Pharmacological Properties of XEN-D0101: A Novel Atrial-Selective Kv1.5/IKur Inhibitor

K. Matschke, D. Madge, L. Virág, 2013, Journal of cardiovascular pharmacology.

Genetic variation in GNB5 causes bradycardia by increasing IK,ACh augmenting cholinergic response.

R. Wilders, C. Bezzina, A. Verkerk, 2019, Disease models & mechanisms.

A benzopyran with antiarrhythmic activity is an inhibitor of Kir3.1-containing potassium channels

Hao Tan, D. Logothetis, G. Thakur, 2021, The Journal of biological chemistry.

Genetic variation in GNB5 causes bradycardia by augmenting the cholinergic response via increased acetylcholine-activated potassium current (IK,ACh)

R. Wilders, C. Bezzina, A. Verkerk, 2019, Disease Models & Mechanisms.

Reduced ryanodine receptor to dihydropyridine receptor ratio may underlie slowed contraction in a rabbit model of left ventricular cardiac hypertrophy.

J. Milnes, K. MacLeod, J. Milnes, 2001, Journal of molecular and cellular cardiology.

Novel K+ Channel Targets in Atrial Fibrillation Drug Development—Where Are We?

J. Milnes, S. El-Haou, J. Ford, 2015, Journal of cardiovascular pharmacology.

Inhibition of HERG K+ Current and Prolongation of the Guinea‐Pig Ventricular Action Potential by 4‐Aminopyridine

J. Hancox, H. Witchel, J. Milnes, 2003, The Journal of physiology.

The N588K-HERG K+ channel mutation in the 'short QT syndrome': mechanism of gain-in-function determined at 37 degrees C.

Jules C Hancox, Harry J Witchel, James T Milnes, 2005, Biochemical and biophysical research communications.

Characterisation of recombinant HERG K+ channel blockade by the Class Ia antiarrhythmic drug procainamide.

J. Hancox, H. Witchel, J. Ridley, 2003, Biochemical and Biophysical Research Communications - BBRC.